If you are wanting to supercharge your portfolio returns, then it could be worth looking at the ASX 200 shares in this article.
They have been named as buys by Macquarie and tipped to rise around 40% to 50% from current levels. Here's what they are recommending to clients:
Neuren Pharmaceuticals Ltd (ASX: NEU)
The team at Macquarie sees major upside potential in this ASX 200 share.
It is a pharmaceuticals company developing new therapies for highly debilitating neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
Macquarie believes that its "current valuation offers favourable risk-reward." Its analysts adds that they "believe DAYBUE in NA is driving most of current share price, with further upside from ROW/ pipeline. Its strong cash position enables pipeline acceleration, potentially providing significant long-term upside if approved."
The broker has an outperform rating and $18.60 price target on its shares. Based on its current share price of $12.54, this implies potential upside of almost 50% for investors.
Web Travel Group Ltd (ASX: WEB)
Another ASX 200 share that could be cheap according to analysts is Web Travel. It is the business to business travel technology company behind the WebBeds business.
After going through a tough period, Macquarie believes that the tide is now turning and it is onwards and upwards for the company.
It recently noted that it has "increased confidence this should be the medium-term floor, given company-driven headwinds have been addressed, such as 1) overrides; 2) European summer pricing; and 3) mgmt focus post demerger."
Macquarie has an outperform rating and $6.19 price target on its shares. Based on the current Web Travel share price of $4.50, this suggests that upside of almost 40% is possible between now and this time next year.
WiseTech Global Ltd (ASX: WTC)
A third ASX 200 share that could be destined to deliver big returns over the next 12 months is WiseTech Global.
Although the logistics software provider's shares have rebounded strongly from their 52-week lows, they are still down heavily from their highs.
The team at Macquarie sees this as a compelling buying opportunity for investors.
The broker currently has an outperform rating and $152.70 price target on its shares. Based on its current share price of $107.24, this implies potential upside of 42% for investors over the next 12 months.
